Recursion Gains European Commission Orphan Drug Status For Rare Tumor Candidate
Recursion (NASDAQ: RXRX) received Orphan Drug Designation for REC-4881 from the European Commission towards the potential treatment of familial adenomatous polyposis (FAP).
